Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Association of Clinical Research Professionals (ACRP)
Jim Kremidas, executive director of ACRP, has announced his retirement, effective May 31. The organization is currently seeking his replacement.
Yoshitsugu Shitaka has been named chief scientific officer of Astellas Pharma. Most recently, Shitaka served as the company’s Institute for Regenerative Medicine president.
BioCurate has appointed Damien Bates, the company’s chief scientific officer, to acting CEO. Bates was a chief medical officer consultant at SanBio prior to joining BioCurate in 2019.
Alvin Shih has been named president and CEO of Catamaran Bio. Prior to joining Catamaran, Shih was CEO of Disarm Therapeutics.
Osamu Okuda, who currently serves as representative director and chief operating officer of Chugai Pharmaceutical, has been named CEO of the company.
Dong Yu has been named senior vice president of vaccine research of Dynavax. Most recently, Yu was head of preclinical R&D U.S. at GlaxoSmithKline Vaccines.
Editas Medicine has named James Mullen as CEO. Mullen has been chairman of the company’s board of directors since 2018 and was previously CEO of Patheon.
Andrew Paterson, the senior vice president and head of the global multiple sclerosis franchise at Merck’s EMD Serono, has assumed the roles of president and global head of innovative medicine franchises of EMD Serono.
Todd Hobbs has joined Hepion Pharmaceuticals as its new chief medical officer. Most recently, Hobbs served as North American chief medical officer at Novo Nordisk.
Matthew Maurer has assumed the role of head of clinical oncology and medical affairs at IDEAYA Biosciences. Previously, Maurer was medical director at Bristol Myers Squibb.
Deborah Wenkert has been appointed senior vice president and chief medical officer of Inozyme Pharma. Prior to Inozyme, Wenkert was chief medical officer of PreciThera.
Ironwood Pharmaceuticals has named Thomas McCourt, the company’s president, as interim CEO after Mark Mallon announced his decision to step down as CEO.
Shannon Blalock has been named CEO of biotech company jCyte. Blalock was previously the global leader for portfolio development and global R&D strategy at Santen Pharmaceuticals.
Frank Neumann, former chief medical officer of Verastem Oncology, has been named head of global clinical development at Gilead Sciences’ Kite.
Koya Medical has named Stanley Rockson chief medical officer. Rockson was the co-founder of Lymphatic Education and Research Network and current professor and chief of consultative cardiology at Stanford University.
Ronald Carter has been named chief medical officer of Microbiotica. Carter previously held the position of chief medical officer at Seres Therapeutics.
Asit Parikh has taken the helm of Moma Therapeutics as its president and CEO. Parikh was recently the senior vice president and head of Takeda Pharmaceutical’s gastroenterology unit.
Monte Rosa Therapeutics
Owen Wallace has joined Monte Rosa Therapeutics as its chief scientific officer. Wallace was most recently chief scientific officer at Fulcrum Therapeutics.
Martin Driscoll has been appointed CEO of OncoNano Medicine. Prior to this appointment, Driscoll was president and CEO of Spring Bank Pharmaceuticals.
Clinical-stage biopharmaceutical company Scholar Rock has appointed Gregory Carven to chief scientific officer. Most recently, Carven was vice president of antibody discovery and protein sciences at Scholar, a position he’s held since 2014. George Nomikos, another new hire at Scholar, has taken on the role of senior vice president of medical and clinical sciences and head of the muscle therapeutic area. Nomikos was previously a senior medical director at Biogen.
Alexander Gebauer has been named CEO and managing director of Secarna Pharmaceuticals. Previously, Gebauer served as CEO and chairman of Omeicos Ophthalmics.